Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].
Polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC] significantly augmented natural killer (NK) cell activity in several tissues. Macrophage (M phi) tumoricidal activity was also markedly increased. Both effector cells were active for 9 days. Poly(I,C)-LC also increased effector cell response in vitro. Injections of poly(I,C)-LC resulted in elevated effector cell responses in four of five routes tested. Treatment with poly(I,C)-LC led to an earlier reconstitution of bone marrow cells, NK cell activity, and M phi effector cell activity in mice pretreated with cyclophosphamide (Cytoxan). Combined treatment of MBL-2 tumor cells with cytoreductive chemotherapy and poly(I,C)-LC resulted in an enhanced therapeutic response.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use / Q000031:analogs & derivatives; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007700:Kinetics; D007942:Leukemia, Experimental / Q000188:drug therapy; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008747:Methylcellulose / Q000031:analogs & derivatives*; D051379:Mice; D011070:Poly I-C / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D011107:Polylysine / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D011107:Polylysine; C019531:poly ICLC; D003520:Cyclophosphamide; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C